Teleflex Incorporated (TFX)

US — Healthcare Sector
Peers: BLCO  MMSI  KRYS  ALKS  PTCT  STVN  BRKR  BTSG  TGTX  OSCR 

Automate Your Wheel Strategy on TFX

With Tiblio's Option Bot, you can configure your own wheel strategy including TFX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TFX
  • Rev/Share 66.431
  • Book/Share 92.6755
  • PB 1.4327
  • Debt/Equity 0.4702
  • CurrentRatio 2.4071
  • ROIC 0.0366

 

  • MktCap 5867922241.0
  • FreeCF/Share 9.4233
  • PFCF 13.6014
  • PE 31.6727
  • Debt/Assets 0.2705
  • DivYield 0.0102
  • ROE 0.0449

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade TFX BofA Securities Neutral Underperform $235 $140 March 4, 2025
Downgrade TFX Piper Sandler Overweight Neutral $255 $140 Feb. 28, 2025
Downgrade TFX Raymond James Outperform Market Perform -- -- Feb. 28, 2025
Downgrade TFX RBC Capital Mkts Outperform Sector Perform $220 $155 Feb. 28, 2025
Downgrade TFX Citizens JMP Mkt Outperform Market Perform -- -- Feb. 27, 2025

News

Did Teleflex Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - TFX
TFX
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.

Read More
image for news Did Teleflex Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - TFX
TFX INVESTIGATION: A Securities Fraud Investigation into Teleflex Incorporated has been Initiated - Investors with Losses are Urged to Contact BFA Law
TFX
Published: March 03, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / March 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE:TFX) for potential violations of the federal securities laws. If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated.

Read More
image for news TFX INVESTIGATION: A Securities Fraud Investigation into Teleflex Incorporated has been Initiated - Investors with Losses are Urged to Contact BFA Law
An Investigation Has Commenced on Behalf of Teleflex Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your TFX Losses.
TFX
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.

Read More
image for news An Investigation Has Commenced on Behalf of Teleflex Incorporated Shareholders. Contact Levi & Korsinsky to Discuss your TFX Losses.
TFX STOCK UPDATE: The Teleflex Incorporated Securities Fraud Investigation is Ongoing; Investors are Urged to Contact BFA Law if they Suffered Losses
TFX
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE:TFX) for potential violations of the federal securities laws. If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated.

Read More
image for news TFX STOCK UPDATE: The Teleflex Incorporated Securities Fraud Investigation is Ongoing; Investors are Urged to Contact BFA Law if they Suffered Losses
TFX STOCK ALERT: A Securities Fraud Investigation has been initiated on behalf of Teleflex Incorporated Investors; Contact BFA Law if You Suffered Losses (NASDAQ:TTD)
TFX, TTD
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE: TFX) for potential violations of the federal securities laws. If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated.

Read More
image for news TFX STOCK ALERT: A Securities Fraud Investigation has been initiated on behalf of Teleflex Incorporated Investors; Contact BFA Law if You Suffered Losses (NASDAQ:TTD)
TFX STOCK NOTICE: Teleflex Incorporated Investors with Losses are Notified of an Ongoing Securities Fraud Investigation; Contact BFA Law
TFX
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE:TFX) for potential violations of the federal securities laws. If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated.

Read More
image for news TFX STOCK NOTICE: Teleflex Incorporated Investors with Losses are Notified of an Ongoing Securities Fraud Investigation; Contact BFA Law
TFX BREAKING NEWS: Teleflex Incorporated 20% Stock Drop Triggers Securities Fraud Investigation; Investors are Urged to Contact BFA Law if they Suffered Losses
TFX
Published: February 27, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)---- $TFX #ClassAction--Teleflex Incorporated investors that lost money are encouraged to contact BFA Law about its ongoing securities fraud investigation.

Read More
image for news TFX BREAKING NEWS: Teleflex Incorporated 20% Stock Drop Triggers Securities Fraud Investigation; Investors are Urged to Contact BFA Law if they Suffered Losses
Teleflex Hits 52-Week Low On Plan To Split Into Two Companies, Reports Mixed Q4 Earnings
TFX
Published: February 27, 2025 by: Benzinga
Sentiment: Negative

On Thursday, Teleflex Incorporated TFX will pursue a plan to separate into two new, independent, publicly traded companies:

Read More
image for news Teleflex Hits 52-Week Low On Plan To Split Into Two Companies, Reports Mixed Q4 Earnings
Teleflex (TFX) Surpasses Q4 Earnings Estimates
TFX
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Teleflex (TFX) came out with quarterly earnings of $3.89 per share, beating the Zacks Consensus Estimate of $3.86 per share. This compares to earnings of $3.38 per share a year ago.

Read More
image for news Teleflex (TFX) Surpasses Q4 Earnings Estimates

About Teleflex Incorporated (TFX)

  • IPO Date 1980-03-17
  • Website https://www.teleflex.com
  • Industry Medical - Instruments & Supplies
  • CEO Liam J. Kelly
  • Employees 14100

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.